Suppr超能文献

洗肠菌群移植联合生物制剂促进难治性重症溃疡性结肠炎合并复发性肠道感染的组织学缓解:一例报告

Washed microbiota transplantation combined with biological agents promotes histological remission in refractory severe ulcerative colitis with recurrent intestinal infection: A case report.

作者信息

Wu Qiong, Yang Liu-Si, Huang Hong-Li, Li Ying-Fei, Zhou Yong-Jian, Xu Hao-Ming

机构信息

Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.

Department of Gastroenterology and Hepatology, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.

出版信息

Arab J Gastroenterol. 2024 Nov;25(4):448-454. doi: 10.1016/j.ajg.2024.07.008. Epub 2024 Jul 29.

Abstract

Ulcerative colitis (UC) is a chronic non-specific colitis disease. In recent years, fecal microbiota transplantation (FMT), including improved washed microbiota transplantation (WMT), and biological agents have helped improve the prognosis of patients with UC. However, a significant number of patients with moderate to severe UC do not get relief from glucocorticoids, immunosuppressants, and TNF-α antagonists. Patients with severe UC are frequently burdened with opportunistic infections and subsequent surgical interventions. Combined treatment modalities are crucial for patients with severe UC and opportunistic infections. Herein, we reported a case of a 25-year-old female with refractory severe UC complicated with recurrent Clostridioides difficile infection and recurrent cytomegalovirus infection for six years. Surgical removal of the affected bowel segment was almost unavoidable. She showed endoscopic and histological recovery after comprehensive WMT and Vedolizumab treatment. The following are our learnings from the case: 1. A combination of WMT and biological agents can potentially obviate the necessity for surgical treatment in patients with refractory severe UC and promote histological remission. 2. Personalized comprehensive treatment and chronic disease management models for patients with UC should be emphasized. 3. WMT can help treat opportunistic infections, which may also strengthen the treatment with gut-targeted biological agents when traditional TNF-α antagonists show poor efficacy.

摘要

溃疡性结肠炎(UC)是一种慢性非特异性结肠疾病。近年来,粪便微生物群移植(FMT),包括改良的洗肠微生物群移植(WMT)和生物制剂,有助于改善UC患者的预后。然而,相当数量的中度至重度UC患者并未从糖皮质激素、免疫抑制剂和肿瘤坏死因子-α拮抗剂中获得缓解。重度UC患者经常面临机会性感染和随后的手术干预。联合治疗模式对重度UC和机会性感染患者至关重要。在此,我们报告了一例25岁女性难治性重度UC患者,该患者并发复发性艰难梭菌感染和复发性巨细胞病毒感染达六年之久。几乎不可避免地需要手术切除受影响的肠段。在接受全面的WMT和维多珠单抗治疗后,她的内镜和组织学表现均恢复正常。以下是我们从该病例中获得的经验教训:1. WMT和生物制剂联合使用可能避免难治性重度UC患者进行手术治疗的必要性,并促进组织学缓解。2. 应强调针对UC患者的个性化综合治疗和慢性病管理模式。3. WMT有助于治疗机会性感染,当传统的肿瘤坏死因子-α拮抗剂疗效不佳时,这也可能加强肠道靶向生物制剂的治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验